Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple myeloma.
The post Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma appeared first on MedCity News.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
